查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1236034

全球出血性疾病治療市場規模和預測：按類型、藥物類別和地區分析，2022-2029年

Global Bleeding Disorders Treatment Market Size study & Forecast, by Type, by Drug Class and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

出血性疾病是一組影響身體形成適當血凝塊能力的疾病。

其症狀包括受傷、手術後大量出血、抽血等。 此外，這種不當的血液凝固主要是由血小板和凝血蛋白等血液成分的缺陷引起的。 出血性疾病通常由紅細胞計數低、維生素 K 缺乏和某些藥物的副作用引起。 血友病患病率的上升和政府為提高對該病的認識而加大力度是推動市場增長的主要因素。

血友病是一種遺傳性出血性疾病，血液無法正常凝固。 在過去的幾十年中，其流行率逐漸增加。 美國疾病控制和預防中心 (CDC) 估計，美國血友病的估計患病率是每 100,000 名美國男性中有 12 人患有 A 型血友病，每 100,000 名美國男性中有 12 人患有 B 型血友病。3.7 例病例，另外還有 30,000 例和 33,000 例美國男性患有血友病。 根據血友病協會的數據，在英國，每 2,000 名男性、女性和兒童中就有 1 人被診斷出患有出血性疾病。 最常見的是馮維勒布蘭德病 (VWD)*，影響該國 7,071 名女性和 4,081 名男性。 此外，預計在預測期內，增加對新興市場的醫療保健投資和推進醫療保健行業的數字化轉型將為市場提供良好的增長前景。 然而，出血性疾病治療的高成本和熟練專業人員的短缺阻礙了整個 2022-2029 年預測期內的市場增長。

全球出血性疾病治療藥物市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於主要市場參與者的存在和該地區醫療保健支出的增加，北美在收入方面佔據了市場主導地位。 另一方面，由於老年人口和目標人群的增加以及對出血性疾病的認識提高等因素，預計亞太地區在預測期內將以最高的複合年增長率增長。

市場近期發展

  • 2022 年 11 月，CSL Behring LLC 的 Hemgenix（etranacogene dezaparvovec）是一種基於腺相關病毒載體的基因治療藥物，獲批用於治療 B 型血友病（先天性 IX），並獲得美國食品和藥物管理局批准用於治療有因子缺陷的成年患者）最近或過去有過危及生命的出血事件或反復發生嚴重的自發性出血事件。

全球市場報告範圍

  • 歷史數據：2019-2020-2021
  • 估算基準年：2021 年
  • 預測期：2022-2029
  • 報告範圍：收入預測、公司排名、競爭格局、增長因素、趨勢
  • 按地區劃分：北美、歐洲、亞太地區、拉丁美洲、世界其他地區
  • 定制範圍：免費報告定制（最多 8 個工作小時）。 按國家、地區和部門劃分的範圍的添加和更改。

本研究的目的是弄清近年來各個領域和國家的市場規模，並對未來幾年的市場規模進行預測。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。

它還提供了關鍵方面的詳細資訊，例如決定市場未來增長的促進因素和挑戰。 此外，它還結合了利益相關者投資的潛在微觀市場機會，以及主要參與者的競爭格局等詳細分析。

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 出血性疾病治療市場，按地區劃分，2019-2029 年
    • 出血性疾病治療市場，按類型，2019-2029
    • 出血性疾病治療市場，按藥物類別，2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章全球出血性疾病藥物市場的定義和範圍

  • 調查目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 本次調查涵蓋的年份
  • 貨幣兌換率

第 3 章出血性疾病藥物全球市場動態

  • 出血性疾病藥物市場影響分析（2019-2029）
    • 市場促進因素
      • 血友病繼續蔓延
      • 政府提高疾病意識的工作越來越積極
    • 市場挑戰
      • 治療出血性疾病的費用很高
      • 缺乏熟練的專業人員
    • 市場機會
      • 增加對新興國家/地區的醫療保健投資
      • 數位化轉型在醫療保健領域不斷擴大

第 4 章出血性疾病藥物全球市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • PEST分析
    • 政治
    • 經濟
    • 社交
    • 技術
  • 最佳投資機會
  • 關鍵成功策略
  • 業內人士的前景
  • 分析師的建議和結論

第 5 章風險評估 COVID-19 影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章出血性疾病藥物的全球市場：按類型分類

  • 市場概況
  • 出血性疾病藥物的全球市場：按類型和性能分類 - 潛力分析
  • 2019-2029 年全球不同類型出血性疾病治療藥物市場的估計和預測
  • 出血性疾病治療市場細分分析
    • A型血友病
    • B型血友病
    • 血管性血友病
    • 其他

第 7 章出血性疾病藥物的全球市場：按藥物類別分類

  • 市場概況
  • 全球出血性疾病藥物市場：按藥物類別、性能-潛力分析
  • 2019-2029 年全球出血性疾病藥物市場按藥物類別的預測和預測
  • 出血性疾病治療市場細分分析
    • 血漿衍生凝血因子濃縮物
    • 重組凝血因子濃縮物
    • 去氨加壓素
    • 抗纖維蛋白溶解藥
    • 纖維蛋白密封劑
    • 其他

第 8 章出血性疾病藥物的全球市場：區域分析

  • 出血性疾病治療市場，按地區劃分的市場概況
  • 北美
    • 美國
      • 按類型估算和預測，2019-2029 年
      • 2019-2029 年按藥物類別的估計和預測
    • 加拿大
  • 歐洲出血性疾病藥物市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲
  • 亞太出血病藥物市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲出血性疾病治療市場概況
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 世界其他地方

第 9 章競爭資訊

  • 頂級市場策略
  • 公司簡介
    • Novo Nordisk A/S
      • 關鍵資訊
      • 概覽
      • 財務（僅當數據可用時）
      • 產品概覽
      • 近期趨勢
    • Baxter International Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Xenetic Biosciences, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi S.A.
    • Amgen, Inc.
    • Janssen Global Services, LLC.
    • Bioverativ, Inc.

第 10 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查的特點
  • 調查先決條件

Global Bleeding Disorders Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bleeding Disorders are a group of disorders that affect body's ability to form proper blood clot. Its symptoms include excessive bleeding after injury, surgery, mensuration among others. Moreover, this improper clotting is mainly caused by defects in blood components such as platelets and/or clotting proteins. Bleeding disorders are generally caused by low red blood cell count, a vitamin K deficiency and side effects from certain medications. The increasing prevalence of Hemophilia and growing government initiatives for disease awareness are key factors driving the market growth.

Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. Its prevalence has progressively increased during the last few decades. According to the Centers for Disease Prevention and Control (CDC) estimates - the estimated prevalence of hemophilia in the United States is 12 cases per 100,000 U.S. males for hemophilia A and 3.7 cases per 100,000 U.S. males for hemophilia B. Additionally, around 30,000 and 33,000 males are living with hemophilia in the country. Moreover, as per The Hemophilia Society - in UK, one in 2,000 men, women and children have a diagnosed bleeding disorder. Additionally, most common is von Willebrand disorder (VWD),*which affects around 7,071 women and 4,081 men in the country. Also, rising healthcare investment in developing regions and growing digital transformation in health care sector would create lucrative growth prospectus for the market over the forecast period. However, the high cost of Bleeding Disorders Treatment and dearth of skilled professionals stifle market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bleeding Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing awareness towards bleeding disorders in the region.

Major market players included in this report are:

  • Novo Nordisk A/S
  • Baxter International Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Xenetic Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • Amgen, Inc.
  • Janssen Global Services, LLC.
  • Bioverativ, Inc.

Recent Developments in the Market:

  • In November 2022, CSL Behring LLC's Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have experienced recent or past life-threatening haemorrhage, or have experienced repeated, severe spontaneous bleeding episodes.

Global Bleeding Disorders Treatment Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, Drug Class, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

By Drug Class

  • Plasma-derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Bleeding Disorders Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Bleeding Disorders Treatment Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Bleeding Disorders Treatment Market, by Drug Class, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Bleeding Disorders Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Bleeding Disorders Treatment Market Dynamics

  • 3.1. Bleeding Disorders Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of Hemophilia
      • 3.1.1.2. Growing government initiatives for disease awareness
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of Bleeding Disorders Treatment
      • 3.1.2.2. Dearth of skilled professionals
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising healthcare investment in developing regions
      • 3.1.3.2. Growing digital transformation in health care sector

Chapter 4. Global Bleeding Disorders Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Bleeding Disorders Treatment Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Bleeding Disorders Treatment Market by Type, Performance - Potential Analysis
  • 6.3. Global Bleeding Disorders Treatment Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Bleeding Disorders Treatment Market, Sub Segment Analysis
    • 6.4.1. Hemophilia A
    • 6.4.2. Hemophilia B
    • 6.4.3. Von Willebrand Disease
    • 6.4.4. Others

Chapter 7. Global Bleeding Disorders Treatment Market, by Drug Class

  • 7.1. Market Snapshot
  • 7.2. Global Bleeding Disorders Treatment Market by Drug Class, Performance - Potential Analysis
  • 7.3. Global Bleeding Disorders Treatment Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 7.4. Bleeding Disorders Treatment Market, Sub Segment Analysis
    • 7.4.1. Plasma-derived Coagulation Factor Concentrates
    • 7.4.2. Recombinant Coagulation Factor Concentrates
    • 7.4.3. Desmopressin
    • 7.4.4. Antifibrinolytics
    • 7.4.5. Fibrin Sealants
    • 7.4.6. Others

Chapter 8. Global Bleeding Disorders Treatment Market, Regional Analysis

  • 8.1. Bleeding Disorders Treatment Market, Regional Market Snapshot
  • 8.2. North America Bleeding Disorders Treatment Market
    • 8.2.1. U.S. Bleeding Disorders Treatment Market
      • 8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. Drug Class breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Bleeding Disorders Treatment Market
  • 8.3. Europe Bleeding Disorders Treatment Market Snapshot
    • 8.3.1. U.K. Bleeding Disorders Treatment Market
    • 8.3.2. Germany Bleeding Disorders Treatment Market
    • 8.3.3. France Bleeding Disorders Treatment Market
    • 8.3.4. Spain Bleeding Disorders Treatment Market
    • 8.3.5. Italy Bleeding Disorders Treatment Market
    • 8.3.6. Rest of Europe Bleeding Disorders Treatment Market
  • 8.4. Asia-Pacific Bleeding Disorders Treatment Market Snapshot
    • 8.4.1. China Bleeding Disorders Treatment Market
    • 8.4.2. India Bleeding Disorders Treatment Market
    • 8.4.3. Japan Bleeding Disorders Treatment Market
    • 8.4.4. Australia Bleeding Disorders Treatment Market
    • 8.4.5. South Korea Bleeding Disorders Treatment Market
    • 8.4.6. Rest of Asia Pacific Bleeding Disorders Treatment Market
  • 8.5. Latin America Bleeding Disorders Treatment Market Snapshot
    • 8.5.1. Brazil Bleeding Disorders Treatment Market
    • 8.5.2. Mexico Bleeding Disorders Treatment Market
    • 8.5.3. Rest of Latin America Bleeding Disorders Treatment Market
  • 8.6. Rest of The World Bleeding Disorders Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Novo Nordisk A/S
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Baxter International Inc.
    • 9.2.3. Alnylam Pharmaceuticals, Inc.
    • 9.2.4. Pfizer, Inc.
    • 9.2.5. Xenetic Biosciences, Inc.
    • 9.2.6. Bristol-Myers Squibb Company
    • 9.2.7. Sanofi S.A.
    • 9.2.8. Amgen, Inc.
    • 9.2.9. Janssen Global Services, LLC.
    • 9.2.10. Bioverativ, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Bleeding Disorders Treatment Market, report scope
  • TABLE 2. Global Bleeding Disorders Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Bleeding Disorders Treatment Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Bleeding Disorders Treatment Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 5. Global Bleeding Disorders Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Bleeding Disorders Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Bleeding Disorders Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Bleeding Disorders Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Bleeding Disorders Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Bleeding Disorders Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Bleeding Disorders Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Bleeding Disorders Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Bleeding Disorders Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Bleeding Disorders Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Bleeding Disorders Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Bleeding Disorders Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Bleeding Disorders Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Bleeding Disorders Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Bleeding Disorders Treatment Market, research methodology
  • FIG 2. Global Bleeding Disorders Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Bleeding Disorders Treatment Market, key trends 2021
  • FIG 5. Global Bleeding Disorders Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Bleeding Disorders Treatment Market, porters 5 force model
  • FIG 7. Global Bleeding Disorders Treatment Market, pest analysis
  • FIG 8. Global Bleeding Disorders Treatment Market, value chain analysis
  • FIG 9. Global Bleeding Disorders Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Bleeding Disorders Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Bleeding Disorders Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Bleeding Disorders Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Bleeding Disorders Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Bleeding Disorders Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Bleeding Disorders Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Bleeding Disorders Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Bleeding Disorders Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Bleeding Disorders Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Bleeding Disorders Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable